This statement applies to Myonex Limited; a private limited company located in one central office in Birstall, Leicestershire, UK. Myonex Limited is a wholly owned subsidiary of Myonex, Inc. located in Norristown, Pennsylvania, USA. Myonex also has a wholly owned subsidiary in Denmark, Myonex ApS. The information included in the statement refers to the financial year to December 2019.
Myonex is a global leader in the clinical trials supply industry. Working with customers and suppliers around the world, Myonex sources, supplies and in some cases packages drugs and other pharmaceutical products for use in clinical trials.
All employees of Myonex Limited are based in the UK and apart from business travel, carry out their work within the UK. Myonex Inc. employees are based in and work from the United States of America. Myonex ApS does not currently have any employees located in Denmark, work on behalf of Myoderm ApS is carried out by Myonex Limited employees based in the UK.
The Company recognises that modern slavery encompasses:
The Company acknowledges its responsibilities in relation to tackling Modern Slavery and commits to complying with the provisions in the Modern Slavery Act 2015. The Company understands that this requires an ongoing review of both its internal practices in relation to its labour force and, additionally, its supply chains.
The Company does not enter into business with any other organisation, in the United Kingdom or abroad, which knowingly supports or is found to involve itself in slavery, servitude and forced or compulsory labour.
All Myonex group companies adhere strictly to the applicable standards required in relation to its responsibilities under relevant employment and Health and Safety legislation in all countries of operation. Specifically, within the UK, all employees are engaged directly by Myonex and enjoy terms and conditions of employment that exceed the minimum requirements set out in law. In response to the global COVID-19 pandemic, all Myonex group companies have organized the workforce such that the vast majority of employees have been able to work from home. Where essential onsite work has had to take place, rigorous social distancing and cleaning protocols have been employed to ensure the safety of our teams and compliance with local regulations and statutory guidance.
In order to fulfil its activities, the main supply chains of the Company include those related to the supply of drugs and ancillary pharmaceutical products from various suppliers in the United Kingdom, the European Union and globally. Prior to working with Myonex, all suppliers are appropriately qualified and annually re-qualified in line with industry standards. Myonex keeps the internal qualification and pre-qualification process under review in order to ensure as far as possible we are able to keep Modern Slavery out of our supply chain.
Whilst Myonex considers that its exposure to slavery/human trafficking is and remains low, it recognises that the main risk exists within its supply chain where manufacturers and suppliers may have operations in countries where protection against breaches of human rights may be limited.
In addition to the existing qualifying and re-qualifying processes already in place, Myonex continues to review its due diligence approach within both the Procurement and Quality divisions. Since our previous statement we have introduced Modern Slavery Risk Assessments as part of our vendor qualification process. The risk assessment is carried out when new vendors are identified and then regularly (at least annually) as part of our ongoing relationship.
To its knowledge, no Myonex group company has ever conducted any business with another organisation which has been found to have involved itself with Modern Slavery. Should any supplier be found to or be reasonably suspected of being involved in Modern Slavery, Myonex has the ability to immediately cease working with them or to cease active negotiations. In response to the COVID-19 global pandemic Myonex has taken steps to add additional questions into the vendor risk assessment process, specifically in relation to additional COVID-19 related measures our vendors have undertaken in order to ensure they and their supply chain remains free from Modern Slavery. We will continue to closely monitor the data received through these risk assessments and will take any action necessary where any concerns may be raised.
Myonex has employment policies in place in relation to anti-corruption and whistleblowing and these may be referenced by employees should they have any concerns in relation to modern slavery. Via our core values, all employees are actively expected to ‘Care for the welfare of all’.
This statement is made in pursuance of Section 54(1) of the Modern Slavery Act 2010 and will be reviewed for each financial year.